M.X.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Proprotein convertase subtilisin/kexin type 9 (PCSK9) negatively regulates the low-density lipoprotein (LDL) receptor (LDLR) in hepatocytes and therefore plays an important role in controlling circulating levels of LDL-cholesterol.
I n 2003, positional cloning identified dominant point mutations (S127R and F216L) of proprotein convertase subtilisin/kexin type 9 (PCSK9) in French families with familial hypercholesterolemia. 1 This finding has led to intense investigation of the role played by PCSK9 in the regulation of lipoprotein metabolism. PCSK9 has emerged as a novel therapeutic target for the treatment of dyslipidemia.
PCSK9, a 692-amino-acid-long glycoprotein, is synthesized in the endoplasmic reticulum as a precursor that undergoes autocatalytic processing in which the propeptide (14 kDa ) is cleaved at the N terminus. The propeptide remains attached noncovalently to the mature peptide after being secreted into circulation. Once in circulation, PCSK9 binds to the low-density lipoprotein (LDL) receptor (LDLR) on the cell surface and is further internalized via clathrincoated pits. The LDLR/PCSK9 complex traffics through the endosome to the lysosome for degradation, resulting in reduced LDLR activity and increased levels of plasma LDL-cholesterol. 2, 3 A gain-of-function mutation of PCSK9 (D374Y) enhances binding of PCSK9 to the LDLR and thus strongly promotes LDLR degradation compared with wildtype PCSK9. 4, 5 The finding that PCSK9 negatively regulates LDLR levels has led to numerous attempts to interfere with the LDLR/PCSK9 interaction through pharmacological means. [6] [7] [8] Although it is well established that PCSK9 negatively regulates LDLR levels, the impact of PCSK9 on apolipoprotein B (apoB) production remains controversial and poorly understood. ApoB is the structural protein of LDL, which is removed from circulation via LDLR. Thus, the regulation of LDLR by PCSK9 might alter apoB levels. Clinically, increased apoB concentration is associated with coronary artery disease. 9 Thus, the question of whether PCSK9 plays a role in apoB production is important.
The production of apoB is regulated at the posttranscriptional level. 10 It has been shown that substantial amounts of newly synthesized apoB are degraded intracellularly. 11 The newly synthesized apoB can be degraded either through ubiquitin-mediated proteasomal degradation 12 or by nonproteasomal degradation, the latter of which involves autophagosomes. 13 Autophagosomes are membrane structures that enclose intracellular substrates and deliver them to lysosomes for disposal, in a process termed autophagy. 14 The apoB protein has been shown to accumulate in this structure, which is in close proximity to cytosolic lipid droplets. 13 It is suggested that autophagy may represent an alternative pathway for the disposal of apoB. 15 The present study was designed to investigate the effect of PCSK9 expression on apoB production and whether PCSK9 regulates apoB levels via autophagy.
We used a second-generation adenovirus vector to achieve long-term (30 days) expression of PCSK9 in mice with or without the LDLR, including C57BL/6, LDLR-deficient (Ldlr −/− ), and LDb (Ldlr −/− Apobec1 −/− ) mice. [16] [17] [18] Teng et al, [16] [17] [18] as well as others, 19 developed the LDb mouse model by deleting the genes encoding the LDLR and the apoB mRNA editing enzyme (Apobec1). In contrast to wild-type mice or Ldlr −/− mice, the phenotype of the LDb mice closely mimics humans with hyperlipidemia characterized by the secretion of apoB100-containing lipoproteins only, with increased plasma levels of LDL-cholesterol and decreased levels of high-density lipoprotein (HDL)-cholesterol. In addition, these LDb mice spontaneously develop severe atherosclerotic lesions, even when fed on a normal chow diet. Thus, LDb mice are distinctly different from Ldlr −/− mice, despite both lacking the LDLR. In the present study, we showed that PCSK9 regulates the synthesis and secretion of apoB in an LDLR-independent fashion. Moreover, our results have provided novel evidence for a physical interaction between PCSK9 and apoB. The PCSK9/apoB interaction inhibits intracellular degradation of apoB via the autophagosome/lysosome pathway, and this, in turn, results in increased secretion of apoB-containing lipoproteins and increased levels of cholesterol and triacylglycerol (TAG).
Materials and Methods

Animal Studies
C57BL/6J, Pcsk9 −/− , and Ldlr −/− mice were purchased from Jackson Laboratory (Bar Harbor, ME). LDb mice were generated in Teng's laboratory, as described previously. [16] [17] [18] Ldlr −/− Apobec1 −/− Pcsk9 −/− triple knockout mice were generated by crossing Pcsk9 −/− with LDb mice and confirming the genotype by polymerase chain reaction. Mice were kept in a barrier facility with a 12:12-hour dark-light cycle, and maintained on a standard laboratory chow diet. All animal experiments were conducted in accordance with the Guidelines of the Animal Protocol Review Committee of the University of Texas Health Science Center at Houston.
The E1-, E2b-, E3-deleted adenovirus type 5 vector pAd-del-pol, adenoviral-cytomegalovirus shuttle vector pD2007MCS, and E.C7 cell line were obtained from Etubics Corporation (Seattle, WA) to produce the adenovirus PCSK9 (Ad-PCSK9) vector. The plasmid vector PCSK9 cDNA containing a FLAG tag was obtained from the laboratory of Dr Jay D. Horton (University of Texas Southwestern Medical Center, Dallas, TX). 20 The detailed construction and production of Ad-PCSK9 is described in Methods in the online-only Data Supplement.
Male C57BL/6J, Ldlr −/− , and LDb mice (n=24 for each group) aged 2 months were transduced with Ad-PCSK9 or Ad-null virus (1×10 10 viral particles per mouse) via tail vein injection. Fasting (≈16 hours) blood samples were collected pre-(day 0) and postadenovirus injection on days 7, 14, 21, and 30 via retro-orbital plexus by using a heparin-coated capillary tube (Fisher Scientific, Pittsburgh, PA). The liver and other tissues were collected, snap-frozen in liquid nitrogen, and stored at −80°C. Detailed lipid analyses, Western blotting analysis, real-time quantitative polymerase chain reaction, and ELISA for mouse PCSK9 and human PCSK9, reagents, and antibodies are described in Methods in the online-only Data Supplement.
Pulse-Chase Analysis of ApoB Biosynthesis in Mouse Primary Hepatocytes
Mouse primary hepatocytes (C57BL/6J, Ldlr −/− , and LDb) were isolated using a modified procedure established by David Moore's laboratory at Baylor College of Medicine, Houston, TX. 21 Detailed information on the primary hepatocytes and pulse-chase experiments is described in Methods in the online-only Data Supplement.
Coimmunoprecipitation of PCSK9 and apoB
McA-RH7777 cells stably expressing human apoB18 or apoB48 were generated as described previously. 22 The method of coimmunoprecipitation is described in detail in Methods in the online-only Data Supplement.
Protein-Protein Interaction: Mammalian Matchmaker Two-Hybrid System
We used the mammalian matchmaker two-hybrid system (Clontech, Mountain View, CA) to examine protein-protein interaction. The detailed method is described in Methods in the online-only Data Supplement.
Autophagosome Isolation
We isolated autophagosomes from cells or mouse liver by using the method described by Stromhaug et al. 23 The detailed method is described in Methods in the online-only Data Supplement.
Duolink In Situ Proximity Ligation Assays and Immunofluorescence Analysis
The in situ proximity ligation assay (PLA) kit was obtained from Olink Bioscience (Uppsala, Sweden). The primary antibodies used for this assay were monoclonal antibody PCSK9 (mC33-Mab1), anti-apoB (Abcam, Cambridge, MA), anti-Apobec1 (gift from Dr Lawrence Chan's laboratory, Baylor College of Medicine), and anti-LDLR (Cayman Chemical, Ann Arbor, MI). Cells (liver hepatocellular cells [HepG2 cells] and HepG2 stably expressing Apobec1 cells) were seeded in a chamber slide (NUNC, Naperville, IL) and cultured overnight at 37°C in the incubator. We modified the standard method to detect LDLR/PCSK9 interaction by fixing the cells in paraformaldehyde and not permeabilizing the cell membrane. The detailed method is described in Methods in the online-only Data Supplement.
Statistical Analysis
All results are expressed as the mean±SD values. We used STAT software to conduct 1-way and 2-way ANOVAs (http://www.stata.com/ capabilities/anova-manova/). For each time point, 1-way ANOVA was used to test for significant difference between the mean values of phenotypes (cholesterol and TAG) of the Ad-PCSK9 group and the control virus Ad-null group. Two-way ANOVA was used to analyze the main and interaction effects of treatment and time on the phenotype. The 2 factors were treatment (Ad-PCSK9 or control virus Ad-null) and time. Two-way ANOVA for significant differences was performed between the mean values of the phenotypes of Ad-PCSK9 and control virus Ad-null and for the relationship between treatment and time. The results are shown in Table I in the online-only Data Supplement. Other statistical comparisons were performed using GraphPad Prism software (version 5) unpaired t tests with 2-tailed P values. A P<0.05 was considered to be statistically significant.
Results
Overexpression of PCSK9 Increases Plasma Cholesterol and TAG Levels in an LDLR-Independent Fashion
To assess the effects of PCSK9 on apoB and lipoprotein metabolism, we expressed a FLAG-tagged human PCSK9 (Ad-PCSK9) by using an E2b-deleted second-generation adenovirus vector that exhibits long-term gene expression and low toxicity. 24, 25 We transduced control virus Ad-null and Ad-PCSK9 to wild-type C57BL/6J mice and Ldlr −/− mice and LDb. As shown in Figure 1A , the levels of overexpressed PCSK9 proteins were similar (≈400-fold above the baseline) in all 3 mouse models studied, and the levels remained elevated 30 days after treatment. Furthermore, as expected, the expressed recombinant PCSK9 protein was biologically active; the expression of PCSK9 in C57BL/6 mice markedly decreased LDLR protein levels in the liver ( Figure 1A) .
Most of the endogenous Pcsk9 mRNA and protein were expressed in the liver, with some expressed in the small intestine also ( Figure 1B ). This is similar to the findings of previous studies. 26, 27 After Ad-PCSK9 transduction, >95% of the adenovirus-mediated PCSK9 gene was expressed in the liver, with minute amounts expressed in other organs such as the spleen, small intestine, heart, and kidney ( Figure 1B ). PCSK9 expression resulted in highly significant increased levels of plasma cholesterol and TAG in all 3 mouse models ( Figure 2A ; Table I in the online-only Data Supplement). The effect of PCSK9 expression on plasma cholesterol and TAG was much greater in C57BL/6 mice than that in the LDLRnull mice (Ldlr −/− and LDb). In C57BL/6 mice, the levels of plasma cholesterol and TAG were increased to an average of 3.7-fold and 8.5-fold, respectively, on PCSK9 expression compared with Ad-null. The increase in the levels of plasma cholesterol and TAG in Ldlr −/− mice were 1.7-fold and 3.4fold, respectively, and 1.5-fold and 1.5-fold, respectively, in LDb mice on PCSK9 expression. The smaller increase in plasma cholesterol and TAG levels on PCSK9 expression in LDLR-null mice was attributable to elevated baseline levels of the lipids in these animals. It was also noted that the increase in plasma TAG was much greater than that observed in plasma cholesterol on PCSK9 expression, suggesting the increased very-low-density lipoprotein (VLDL) secretion. The present results showing an effect of PCSK9 expression on plasma lipid levels in C57BL/6 mice are in accord with previous observations. 20, [28] [29] [30] [31] The effect of PCSK9 expression on plasma lipids in the LDLR-null mouse models is in agreement with results reported by Benjannet et al 28 showing increased plasma lipid levels in Ldlr −/− mice.
Fractionation of plasma lipoproteins by fast protein liquid chromatography showed that the increased cholesterol and TAG levels on PCSK9 expression were mainly associated with VLDL and LDL (but not HDL) in all 3 mouse models examined ( Figure IA and IB, respectively in the online-only Data Supplement). In agreement with the total plasma lipid data (Figure 2A) , an increase in TAG levels was more pronounced than that for cholesterol, suggesting further that PCSK9 expression promotes VLDL production, irrespective of the LDLR.
To determine whether PCSK9 expression had an effect on lipid metabolism, we quantified the mRNA of the genes involved in lipid metabolism by using real-time quantitative polymerase chain reaction. No consistent differences were noted in the expression of cholesterol synthesis genes ( Figure   IIA Figure IIC in the onlineonly Data Supplement) between mice transduced with Ad-PCSK9 or Ad-null. Moreover, no significant differences were noted in the protein levels of these gene products, as determined by Western blotting analysis ( Figure IIIA and IIIB in the online-only Data Supplement). Our results, in agreement with previous studies, 20, 29 indicate that PCSK9 expression has no obvious effects on the genes governing cholesterol and TAG biosynthesis.
Overexpression of PCSK9 Increases Plasma ApoB Levels in an LDLR-Independent Fashion
Expression of PCSK9 markedly increased plasma apoB levels in all 3 mouse models studied ( Figure 2B ). On day 7 after PCSK9 expression, plasma apoB100 and apoB48 levels had markedly increased in both C57BL/6 and LDb mice. The apoB levels remained elevated throughout the 30-day study. In C57BL/6 mice, PCSK9 expression resulted in The closed bars represent the levels of plasma cholesterol and TAG, respectively, from the Ad-PCSK9-treated mice. *Statistical analysis was performed using 2-way ANOVA, and the differences between the Ad-PCSK9 and Ad-null groups were highly significant ( Table I in 1.93-, 3.79-, 2.22-, and 1.68-fold increases in apoB100 levels on days 7, 14, 21, and 30, respectively. Likewise, apoB48 levels were increased 3.53-, 4.73-, 4.34-, and 2.0-fold on days 7, 14, 21, and 30, respectively. Similar increases in apoB100 levels were also observed in LDb mice from day 7 to day 30 on PCSK9 expression. In Ldlr −/− mice, the increase in apoB100 and apoB48 levels was prominent on day 14 and maintained through day 30. Fractionation of plasma lipoproteins revealed that the increased apoB100 and apoB48 levels were associated with VLDL and LDL fractions ( Figure IVA 
PCSK9 Is Associated With VLDL and LDL, But Mostly With LDL
Next, we determined whether PCSK9 is associated with apoBcontaining lipoprotein particles. We measured endogenous mouse plasma PCSK9 levels in nontreated C57BL/6, Ldlr −/− , and LDb mice by using ELISA (92±7.8, 2015±140, and 1646±380 ng/mL, respectively); mice lacking LDLR had ≈20-fold more PCSK9 than wild-type C57BL/6 mice. Fractionation of plasma lipoproteins showed that 30% and 41% of plasma PCSK9 was associated with LDL in Ldlr −/− and LDb mice, respectively ( Figure 3A) . The PCSK9 level in C57BL/6 mice was too low to calculate percentage distribution. Taken together, our results demonstrate that a substantial amount of endogenous PCSK9 is associated mostly with LDL in circulation.
Next, we examined the distribution of overexpressed PCSK9 in plasma lipoproteins; PCSK9 was predominantly present in the LDL fractions from day 7 to day 30 in LDb mice ( Figure 3B ). When we concentrated the plasma fractions of VLDL, LDL, and HDL of C57BL/6, LDb, and Ldlr −/− mice, PCSK9 was detected in both VLDL and LDL, but not in HDL fractions, as shown on day 7 after Ad-PCSK9 transduction Figure 3C ). These results indicate that PCSK9 is associated with both VLDL and LDL, but mostly with LDL particles.
PCSK9 Interacts With apoB
To gain an insight into the mechanisms by which PCSK9 expression affects apoB production, we examined the possibility of a protein-protein interaction between PCSK9 and apoB. We used 3 different approaches. First, a PCSK9/apoB interaction was demonstrated by coimmunoprecipitation using an anti-FLAG antibody on cell lysates and media of McA-RH7777 cells stably expressing human apoB18 or apoB48 (representing the N terminus, 18% and 48% of the full-length apoB100, respectively) transduced with Ad-PCSK9 (+) or Ad-null (−). As shown in Figure 4A , apoB18 and apoB48 coimmunoprecipitated with PCSK9 in both cell lysates and media. ApoB was not detected in the precipitates from the control cells transduced with Ad-null. These results suggested that PCSK9 could bind to amino acid sequences within the N-terminal region of apoB, namely, apoB18. In addition, the association of PCSK9 with apoB occurred intracellularly and in the media.
Second, the PCSK9/apoB18 interaction was determined with a mammalian matchmaker two-hybrid system using secreted alkaline phosphatase (SEAP) as the reporter. 32 Cotransfection of 293 cells or COS-1 cells with plasmids encoding pVP16-PCSK9, pM-apoB18, and pG5SEAP reporter resulted in >10fold SEAP activity (measured by ELISA) compared with the controls (ie, transfected with VP16-PCSK9/pG5SEAP, pM-apoB18/pG5SEAP, pM-Apobec1/pVP16-PCSK9/pG5SEAP, or pM/pVP16/pG5SEAP; Figure 4B ). The interaction of PCSK9/apoB18 in 293 cells was even stronger than that of PCSK9/LDLR in transfected 293 cells ( Figure 4B, right) . These results suggest that PCSK9 can bind to apoB intracellularly.
Third, we used an in situ PLA, termed Duolink in situ PLA, to determine the intracellular interaction between endogenous PCSK9 and apoB100 in HepG2 cells. Duolink in situ PLA detects protein-protein interactions (within 40 nm) at physiological concentrations with high specificity. 33 In HepG2 cells, apoB and PCSK9 were detected in the cytoplasm whereas the LDLR was localized to the membranes (Figure 4C, top) . In HepG2 stably expressing Apobec1 cells, Apobec1 and PCSK9 were also detected in the cytoplasm (Figure 4C, bottom) . Figure 4D shows that endogenous apoB100 interacted with PCSK9 in the cytoplasm of HepG2 cells, as determined by Duolink in situ PLA ( Figure 4D , top marked αApoB/αPCSK9 in red dots). As expected, there was also a detectable interaction signal between PCSK9 and LDLR (top marked αLDLR/ αPCSK9). The following control experiments are not shown here because no signals were detected in the HepG2 cells hybridized with only anti-apoB or anti-PCSK9 antibodies, no antibody control, between PCSK9 and GAPDH, or between apoB and GAPDH. Although Apobec1 did not interact with PCSK9 (αApobec1/αPCSK9) in HepG2 stably expressing Apobec1 cells, a strong interaction between apoB and PCSK9 was observed again in the cytoplasm of these cells ( Figure  4D , bottom marked αApoB/αPCSK9). Collectively, these 3 different approaches confirmed a physical interaction between PCSK9 and apoB within the hepatocytes.
Increased Synthesis/Secretion and Decreased Autophagic Degradation of ApoB on PCSK9 Expression
We next performed pulse-chase experiments to determine the impact of the PCSK9/apoB interaction on apoB biosynthesis by using primary hepatocytes isolated from C57BL/6, Ldlr −/− , and LDb mice. The hepatocytes were transduced with either Ad-PCSK9 or Ad-null vectors. The hepatocytes were then pulsed with 35S-methionine/cysteine for 15 minutes and chased for 30, 60, 120, 180, and 240 minutes. PCSK9 expression in the hepatocytes of C57BL/6 mice significantly increased the incorporation of 35S-methionine/cysteine into apoB100 and apoB48 in cell lysates compared with Ad-null transduced cells ( Figure 5A) . Similarly, primary hepatocytes − , B) , and LDb (C) mice. Cells were plated onto a 6-well plate coated with mouse type IV collagen, followed by overnight incubation with either Ad-null or Ad-PCSK9. On the next day, the cells were labeled with 35S-methionine/cysteine (35S-Met/-Cys) for 30 minutes, and chased for 30, 60, 120, 180, and 240 minutes. Cell media and cell lysates were immunoprecipitated with anti-mouse apoB antibody and protein A agarose, followed by SDS-PAGE. The bands of apoB100 and apoB48 in C57BL/6 and Ldlr −/− , and apoB100 in LDb mice hepatocytes were scanned by PhosphorImager and quantified using Quantity One software. The results are expressed as total radioactivity of each band (mean±SD). *P<0.05, comparing the Ad-PCSK9 group to the Ad-null group. A representative gel image is shown. The experiments were performed 3× with duplicate samples for each time point.
of Ldlr −/− mice expressing PCSK9 had significantly increased incorporation of 35S-methionine/cysteine into apoB100 and apoB48 in both cell lysates and media ( Figure 5B ), and the incorporation of methionine into apoB100 in LDb mice was ≈3-fold higher than that in either C57BL/6 or Ldlr −/− mice. The effect of PCSK9 expression on apoB synthesis is specific, because no effect was observed for albumin synthesis. Thus, our results demonstrated that PCSK9 increased apoB biosynthesis in C57BL/6 mice containing the LDLR and in Ldlr −/− and LDb mice deficient for the LDLR. The increased production of apoB in PCSK9-transduced hepatocytes could not be attributed to increase apoB gene expression, because quantification of the apoB mRNA showed no difference between PCSK9-expressing cells and control cells ( Figure V in the online-only Data Supplement).
We next determined the effect of PCSK9 expression on intracellular degradation of apoB through the autophagosome/lysosome pathway. 13, 34 First, we transfected PCSK9 into McA-RH7777 cells and determined the concentration of apoB and light chain protein 3 (LC3) 14 in isolated autophagosomes. As shown in Figure 6A , the ratios of apoB100:LC3 and apoB48:LC3 were significantly lower in the cells expressing PCSK9, compared with those in control cells (ie, transfected with vector). Thus, expression of PCSK9 in McA-RH7777 cells resulted in decreased apoB (apoB100 and apoB48) levels in autophagosomes.
To examine the effect of endogenous PCSK9 on apoB levels, we compared the apoB levels in autophagosomes isolated from the livers of Ldlr −/− mice with or without PCSK9 (LDb=Ldlr −/− Apobec1 −/− Pcsk9 +/+ mice and LDbPcsk9 −/− =Ldlr −/− Apobec1 −/− Pcsk9 −/− mice, respectively). Similar to what was observed in McA-RH7777 cells, the ratio of apoB100:LC3 was significantly lower in LDb mice (Ldlr −/− Apobec1 −/− Pcsk9 +/+ ) compared with that in LDbPcsk9 −/− triple knockout mice ( Figure 6B ). Thus, there was less apoB in the autophagosomes in Pcsk9-positive mice (LDb), which suggested that decreased amount of apoB was shunted to autophagosomes for degradation and more apoB was subjected to secretion. This was reflected on LDbPcsk9 −/− triple knockout mice, which had significantly decreased plasma levels of apoB (↓ 34%), cholesterol (↓ 29%), and TAG (↓ 33%) compared with LDb mice.
Finally, we determined whether the effect of PCSK9 on apoB degradation was dependent on the LDLR by comparing apoB100:LC3 and apoB48:LC3 ratios in autophagosomes isolated from C57BL/6 and Pcsk9 −/− mice. As shown in Figure 6C , C57BL/6 mice (Pcsk9 +/+ ) had significantly less apoB100:LC3 and apoB48:LC3 ratios in autophagosomes compared with Pcsk9 −/− mice. The Pcsk9 −/− mice have lower plasma cholesterol (↓ 53%) and apoB48 levels compared with C57BL/6 mice. 35 These results together suggest that PCSK9 expression in the mouse liver inhibits apoB from autophagic degradation and this process is independent of the LDLR.
Discussion
The present study demonstrates that long-term expression of PCSK9 in mice, irrespective of the presence of the LDLR, increases plasma cholesterol, TAG, and apoB levels. PCSK9 interacts with apoB to prevent/inhibit/decrease the mobilization of apoB toward autophagosomes for degradation via the autophagosome/lysosome pathway. This, in turn, results in increased production and secretion of apoB and apoBcontaining lipoproteins. Most importantly, our study demonstrates a direct protein-protein interaction of PCSK9 and apoB in cells under physiological conditions. Taken together, these data establish that PCSK9 regulates apoB metabolism independent of the LDLR. The present study provides a new mode by which PCSK9 could regulate apoB degradation, and suggests the importance of lowering PCSK9 levels to reduce the production/secretion of apoB-containing lipoproteins.
Previous investigations involving cells, 4 mice, 28 and humans 36 have suggested that PCSK9 might play a role in regulating apoB production, but other studies failed to observe an effect of PCSK9 on apoB production. 30, 37 Evidence from the present study led us to conclude that these discordances might have resulted from experimental designs; those studies were terminated too early (3-6 days). Most importantly, we used 3 different methods, coimmunoprecipitation, mammalian matchmaker two-hybrid system, and Duolink in situ PLA, to show that PCSK9 interacts with apoB. These results provided convincing evidence of a direct endogenous protein-protein interaction of PCSK9 with apoB. Previous studies have shown that PCSK9 mutants such as D374Y 4 and S127R 36 exert greater effect on increasing apoB production than wild-type PCSK9. Patients with D374Y mutation in PCSK9 have a particularly severe form of autosomal dominant hypercholesterolemia. 38 The D374Y mutant form of PCSK9 binds to the LDLR and results in reduced LDLR activity 10-fold greater than that observed for wild-type PCSK9. 4, 29 These mutants might also have higher binding affinity toward apoB. Further study is warranted to elucidate the structure-function relationship between PCSK9 and apoB.
Zhang et al 39 have demonstrated that PCSK9 selectively interacts with the epidermal growth factor-A repeat of the LDLR (but not with other members of the LDLR family) in a calcium-dependent manner. Moreover, they 40 have shown that the PCSK9-mediated degradation of the LDLR requires the LDLR ligand-binding domain and the β-propeller domain. Further, the prodomain, catalytic domain, and C-terminal domain of PCSK9 are all essential for PCSK9-mediated degradation of the LDLR. ApoB is a large protein with a molecular weight of 550 kDa. Now that we know that apoB18 interacts with PCSK9 efficiently, the question will be whether the interaction of apoB18 with PCSK9 is sufficient to inhibit apoB from moving to the autophagosome for degradation. Furthermore, the PCSK9-binding site on the LDLR is distinct from the ligand-binding region that recognizes the LDL particle. 39 Because we have shown that PCSK9 associates with LDL, it would be of interest to determine whether PCSK9 can mask the LDLR-binding domain of apoB. In that case, the PCSK9-associated LDL would not be taken up by the LDLR. These questions remain to be addressed experimentally.
ApoB is constitutively expressed in the liver 10 and is regulated at the posttranscriptional and translational levels. Various mechanisms have been proposed for Figure 6 . Proprotein convertase subtilisin/kexin type 9 (PCSK9) expression decreases the levels of apolipoprotein B100 (apoB100) and apoB48 in hepatic autophagosomes. A, Autophagosomes were isolated from McA-RH7777 cells transfected with either pcDNA3 vector or pcDNA3-PCSK9 vector. B, Hepatic autophagosomes were isolated from LDb and LDbPcsk9 −/− mice. C, Hepatic autophagosomes were isolated from C57BL/6 and Pcsk9 −/− mice. The lysed autophagosomes (30 µg) were subjected to Western blotting analysis to detect apoB100, apoB48, PCSK9, and light chain 3-II (LC3-II). Each protein was detected and quantified using an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE). The results are expressed as a ratio of the intensities of apoB100:LC3-II and apoB48:LC3-II and are shown as mean±SD. *P<0.05 compared with the corresponding samples. The assays were performed 3× with duplicate samples.
the intracellular degradation of apoB. They include an endoplasmic reticulum-associated degradation mediated by the proteasome pathway, 41 a postendoplasmic reticulum presecretory proteolysis possibly mediated through the autophagosome/lysosome pathway, 15, 34 and a LDLRmediated presecretory apoB degradation possibly mediated by the proteasome pathway. 42, 43 Collectively, it is likely that 2 major degradation pathways for apoB exist in hepatocytes: the proteasome pathway and the autophagosome/lysosome pathway. In the endoplasmic reticulum, some of the apoB might interact with LDLR and be degraded through the proteasome pathway. 42, 43 In this case, if LDLR were dysfunctional, the cells would increase the secretion of apoBcontaining lipoproteins. We propose an LDLR-independent apoB degradation process. ApoB is found in cytoplasmic lipid droplets as apoB-crescents, 13 which fuse with autophagosomes/ lysosomes for degradation. This process is likely to be the preferred or more important pathway for apoB degradation. In the present study, we demonstrated PCSK9-regulated apoB degradation in hepatocytes, independent of LDLR. The physical interaction of PCSK9 with apoB acts to shunt apoB away from autophagosomes and degradation. In turn, most of the apoB would be destined for assembly and secretion as VLDL from hepatocytes. This observation is consistent with increased apoB production on overexpression of PCSK9. This is the first report linking PCSK9 regulation of apoB to apoB degradation via the autophagosome/lysosome pathway.
Autophagy is an essential cellular regulatory process that mediates degradation in lysosomes, and it is involved in normal and pathological pathways. Oxidized LDL is removed through the autophagosome/lysosome pathway in human vascular endothelial cells. 44 Moreover, LDL is broken down in activated macrophages via autophagy. 45 It would be interesting to determine whether the association of PCSK9 with LDL via apoB would inhibit the uptake of LDL via macrophages, and in turn, hinder the removal of lipids through an autophagy-mediated efflux process. Thus, our study has raised many unexpected questions related to PCSK9/apoB/LDL that remain to be answered.
In summary, we have demonstrated the important discovery that PCSK9 interacts with apoB, and this interaction leads to decreased degradation of apoB via the autophagosome/ lysosome pathway. The present study also provides evidence for how overexpression of PCSK9 increased cholesterol, TAG, and apoB levels, independent of LDLR. Taken together, our results suggest that decreasing intracellular PCSK9 levels may represent a new therapeutic approach for regulating the production of atherogenic apoB-containing lipoproteins.
